Cytokinetics (MIL:1CYTK) Cyclically Adjusted PB Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1CYTK Cytokinetics Inc MIL:1CYTK
34 GF Score
Price €66.14
GF Value €178.09
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cytokinetics  (MIL:1CYTK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cytokinetics Cyclically Adjusted PB Ratio Related Terms


Cytokinetics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cytokinetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics Cyclically Adjusted PB Ratio Chart

Cytokinetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.38 27.44 74.02 61.97 434.90

Cytokinetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.71 161.47 434.90 0.00 0.00

MIL:1CYTK vs SMMT, TECH, BMRN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PB Ratio falls into.


MIL:1CYTK
34GF Score
Cytokinetics Inc MIL:1CYTK
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytokinetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cytokinetics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cytokinetics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.085/333.9520*333.9520
=-1.085

Current CPI (Jun. 2026) = 333.9520.

Cytokinetics Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.831 241.428 2.533
201612 2.201 241.432 3.044
201703 2.054 243.801 2.814
201706 2.914 244.955 3.973
201709 2.290 246.819 3.098
201712 1.720 246.524 2.330
201803 1.496 249.554 2.002
201806 1.178 251.989 1.561
201809 0.817 252.439 1.081
201812 0.417 251.233 0.554
201903 0.054 254.202 0.071
201906 -0.075 256.143 -0.098
201909 -0.305 256.759 -0.397
201912 -0.166 256.974 -0.216
202003 -0.696 258.115 -0.900
202006 -1.157 257.797 -1.499
202009 1.799 260.280 2.308
202012 1.312 260.474 1.682
202103 0.796 264.877 1.004
202106 0.190 271.696 0.234
202109 2.525 274.310 3.074
202112 2.545 278.802 3.048
202203 1.234 287.504 1.433
202206 1.227 296.311 1.383
202209 -0.171 296.808 -0.192
202212 -1.074 296.797 -1.208
202303 -2.237 301.836 -2.475
202306 -3.205 305.109 -3.508
202309 -4.272 307.789 -4.635
202312 -3.485 306.746 -3.794
202403 -3.479 312.332 -3.720
202406 0.858 314.175 0.912
202409 -0.106 315.301 -0.112
202412 -1.094 315.605 -1.158
202503 -2.067 319.799 -2.158
202506 -2.673 322.561 -2.767
202509 -3.636 324.800 -3.738
202512 -4.582 324.054 -4.722
202603 -5.755 330.213 -5.820
202606 -1.085 333.952 -1.085

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cytokinetics (MIL:1CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €66.14 is trading 62.9% below its estimated GF Value™ of €178.09. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for MIL:1CYTK:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €178.09 vs. price of €66.14 (62.9% below fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the MIL:1CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytokinetics Business Description

Other Exchanges CYTK:USAKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
34GF Score

Get the complete analysis for MIL:1CYTK

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.14
Price
€178.09
GF Value